- Report
- July 2024
- 175 Pages
Global
From €4753EUR$5,000USD£3,993GBP
- Clinical Trials
- December 2024
- 60 Pages
Global
From €1426EUR$1,500USD£1,198GBP
- Report
- March 2025
- 190 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- October 2024
- 183 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- August 2024
- 175 Pages
Global
From €4753EUR$5,000USD£3,993GBP
- Report
- May 2024
- 133 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Report
- July 2024
- 125 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- November 2024
- 180 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- December 2023
- 180 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Drug Pipelines
- March 2022
- 76 Pages
Global
From €3755EUR$3,950USD£3,155GBP
- Report
- January 2022
- 200 Pages
Global
From €7130EUR$7,500USD£5,990GBP
- Report
- August 2023
- 117 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- January 2024
- 200 Pages
Global
From €3945EUR$4,150USD£3,314GBP
- Report
- July 2022
- 136 Pages
Global
From €1901EUR$2,000USD£1,597GBP

The Peanut Allergy Drug market is a subset of the Allergy Drugs market, which is composed of pharmaceuticals used to treat allergic reactions. Peanut Allergy Drugs are specifically designed to treat allergic reactions to peanuts, which can range from mild to life-threatening. These drugs are typically administered in the form of an injection, and are designed to reduce the severity of allergic reactions.
The Peanut Allergy Drug market is highly competitive, with a number of companies offering products to treat peanut allergies. These companies include Aimmune Therapeutics, DBV Technologies, and Allergen Research Corporation. Other companies in the market include AnaptysBio, Inc., and Allergy Therapeutics plc. Show Less Read more